Second-line tarlatamab improves OS in SCLC



Summary

Second-line treatment with tarlatamab, a DLL3-targeting bispecific T-cell engager, significantly improved overall survival (OS) in patients with relapsed or refractory small cell lung cancer (SCLC) compared to standard chemotherapy. The Phase 3 DeLLphi-301 trial demonstrated a statistically significant and clinically meaningful OS benefit, establishing tarlatamab as a promising new option for this aggressive cancer with limited treatment options after initial therapy. This advancement offers hope for improved outcomes in a population with a high unmet need.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!